Cargando…

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis

Viral hepatitis is among the top four causes of mortality globally, causing 1.4 million deaths each year, exceeding tuberculosis, malaria and human immunodeficiency virus. Hepatitis B and C are responsible for 90% of hepatitis deaths, and the remaining 10% are caused by other hepatitis viruses. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soriano, Vicente, Alvarez, Carmen, Edagwa, Benson, de Mendoza, Carmen, Montoya, Noemí, Treviño, Ana, Gendelman, Howard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204217/ https://www.ncbi.nlm.nih.gov/pubmed/34728344 http://dx.doi.org/10.1016/j.ijid.2021.10.052

Ejemplares similares

Limapakgsin ixlilakkaxlan xla pulataman Veracruz xla Ignacio de la Llave
Publicado: (2012)

The Implications of the Cloning of the XLA Gene
por: Flinter, F A, et al.
Publicado: (1993)

ProTide generated long-acting abacavir nanoformulations
por: Lin, Zhiyi, et al.
Publicado: (2018)

A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy
por: Araínga, Mariluz, et al.
Publicado: (2017)

Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes
por: Edagwa, Benson J., et al.
Publicado: (2014)

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation
por: Deodhar, Suyash, et al.
Publicado: (2022)

Creation of a Long-Acting Nanoformulated 2′,3′-Dideoxy-3′-Thiacytidine
por: Guo, Dongwei, et al.
Publicado: (2017)

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
por: McMillan, JoEllyn, et al.
Publicado: (2017)

A mutation in the promoter region of BTK causes atypical XLA
por: Bravo García-Morato, María, et al.
Publicado: (2020)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Response to mRNA COVID-19 vaccination in three XLA patients
por: Squire, J.D., et al.
Publicado: (2022)

Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation
por: Ibrahim, Ibrahim M, et al.
Publicado: (2019)

Magnetic resonance imaging of folic acid-coated magnetite nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapy
por: Li, Tianyuzi, et al.
Publicado: (2015)

Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles
por: Cobb, Denise A., et al.
Publicado: (2021)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Creation of a long-acting nanoformulated dolutegravir
por: Sillman, Brady, et al.
Publicado: (2018)

Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus
por: Cachay, Edward R, et al.
Publicado: (2019)

X-linked agammaglobulinemia (XLA): Phenotype, diagnosis, and therapeutic challenges around the world
por: El-Sayed, Zeinab A., et al.
Publicado: (2019)

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
por: Soriano, Vicente, et al.
Publicado: (2023)

Need to Face Liver Cirrhosis after HCV Cure with Antivirals
por: Soriano, Vicente, et al.
Publicado: (2017)

Development of a Multiplex Real-Time PCR Assay for the Newborn Screening of SCID, SMA, and XLA
por: Gutierrez-Mateo, Cristina, et al.
Publicado: (2019)

Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
por: Bade, Aditya N., et al.
Publicado: (2021)

Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors
por: Foster, Emma G., et al.
Publicado: (2023)

A Comparative Study on the Biosorption of Cd(2+) onto Paecilomyces lilacinus XLA and Mucoromycote sp. XLC
por: Xia, Lu, et al.
Publicado: (2015)

Hypozincemia in Chronic Hepatitis C Is Improved with Viral Clearance by Direct-acting Antiviral Agents
por: Shirahashi, Ryosaku, et al.
Publicado: (2021)

An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression
por: Das, Srijanee, et al.
Publicado: (2022)

Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA)
Publicado: (1994)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector
por: Seymour, Brenda J., et al.
Publicado: (2021)

EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment
por: Gu, Chao-Jiang, et al.
Publicado: (2018)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Prodrug Therapies for Infectious and Neurodegenerative Diseases
por: Markovic, Milica, et al.
Publicado: (2022)

Study on Microstructural Evolution and Mechanical Properties of Mg-3Sn-1Mn-xLa Alloy by Backward Extrusion
por: Zhang, Xuefei, et al.
Publicado: (2023)

A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
por: Adiwijaya, Bambang S., et al.
Publicado: (2012)

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
por: Abdulla, Maheeba, et al.
Publicado: (2019)

Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2021)

Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2020)

Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis
por: Shahnaz, Gul, et al.
Publicado: (2017)

Transcriptome profiling of monocytes from XLA patients revealed the innate immune function dysregulation due to the BTK gene expression deficiency
por: Mirsafian, Hoda, et al.
Publicado: (2017)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g2dst1j8dbchanqsi6vvgri8ri